Bromocriptine (12-Br-a-ergocryptine mesylate), a dopa¬ mine agonist, is a specific inhibitor of prolactin release from the anterior pituitary. While bromocriptine has proven effective in treating hyperprolactinemic anovulation, some normoprolactinemic patients have also res¬ ponded to bromocriptine. Therefore, bromocriptine has been widely used clinically not only in hyperprolactine¬ mic cases, but also in cases of amenorrhea ( 1 ) and luteal insufficiency (2) in normoprolactinemic states. Its mech¬ anism of action is considered to involve the restoration of ovarian function by a decrease in serum prolactin levels (3, 4) . It has also been reported that the effectiveness of bromocriptine in normoprolactinemic anovulatory patients may be due to the stimulation of secretion of gonadotropin-releasing hormone (GnRH) or gonadotropins ( 1 (Fig. 7) .
The bromocriptine-induced mobilization of Ca2 (Fig. 8) .
Discussion
Various changes in steroidogenesis have been observed in studies involving the administration of bromocriptine. For instance, in the rat ovary, 20a-hydroxysteroid dehydrogenase activity increased after administration of a single dose of bromocriptine by injection on day 5, but not when it was given on day 16 of pregnancy. This effect was counteracted by injecting prolactin (3) . These findings were considered due to a reduction of circulat¬ ing prolactin by bromocriptine rather than to its direct effect. In contrast, another in vitro study demonstrated that dopamine stimulates the formation of cAMP in parathyroid gland cells and stimulates the release of parathyroid hormone, suggesting a direct effect of dopamine on the parathyroid gland (7) .
There are numerous reports on the direct inhibitory effects of prolactin on the ovary. Veldhuis et al. (8, 9) and Wang et al. ( 10) have shown that high levels of prolactin can inhibit the FSH induction of aromatase activity, thus reducing estradiol in porcine and rat granulosa cells. In other studies (11, 12) , high levels of prolactin were also shown to inhibit the secretion of progesterone by human granulosa cells in vitro. However, the role of prolactin on the ovarian activity of patients with normoprolactine¬ mic states has received little attention. McGarrigle et al. (14) and GnRH analog (15) , directly affect the steroido¬ genesis by the granulosa cells. The bromocriptinerelated changes in the present study seem to occur in two different ways: by stimulating the secretion of progest¬ erone, and by inhibiting the secretion of estradiol. It may be speculated that bromocriptine inhibits aromatase activity. In our experiments, significant effects of bromo¬ criptine on steroidogenesis without the increase of cell growth were demonstrated at concentrations of 10" mol/l through 10" mol/l. In patients who were admi¬ nistered a single oral dose of bromocriptine 2.5 mg, the serum concentration of bromocriptine reached 10" mol/l (16) . Therefore, the doses of BRC used in this in vitro study are not necessarily pharmacological. The ovarian cAMP of the signal-transducing pathway has been extensively studied with regard to granulosa cell and follicular maturation (1 7, 18 
